IRVINE, Calif., Sept. 17 SpectrumPharmaceuticals, Inc., (Nasdaq: SPPI) announced today that it will present anoverview of the Company on Tuesday, September 18, 2007, at 4:00 p.m.Eastern/1:00 p.m. Pacific, at the ThinkEquity Partners' 5th Annual GrowthConference, being held at the St. Regis Hotel in San Francisco, California.Spectrum's presentation will be given in the Modernist room.
The live webcast of Spectrum's presentation will be available athttp://www.spectrumpharm.com. Replays will be available for 30 days.
About Spectrum Pharmaceuticals
Spectrum Pharmaceuticals acquires, develops and commercializes adiversified portfolio of oncology drug candidates that meet critical healthchallenges for which there are few other treatment options. The company'spipeline includes promising early and late-stage drug candidates with uniqueformulations and mechanisms of action that address the needs of seriously illpatients, such as at-home chemotherapy and new treatment regimens forrefractory disease. For more information, please visit our website athttp://www.spectrumpharm.com.
Forward-looking statement -- This press release may containforward-looking statements regarding future events and the future performanceof Spectrum Pharmaceuticals that involve risks and uncertainties that couldcause actual results to differ materially. These statements include but arenot limited to statements that relate to our business and its future,Spectrum's ability to identify, acquire, develop and commercialize itsportfolio of drug candidates, the Company's promising pipeline, and anystatements that relate to the intent, belief, plans or expectations ofSpectrum or its management, or that are not a statement of historical fact.Risks that could cause actual results to differ include the possibility thatour existing and new drug candidates, may not prove safe or effective, thepossibility that our existing and new drug candidates may not receive approvalfrom the FDA, and other regulatory agencies in a timely manner or at all, thepossibility that our existing and new drug candidates, if approved, may not bemore effective, safer or more cost efficient than competing drugs, thepossibility that our efforts to acquire or in-license and develop additionaldrug candidates may fail, our lack of revenues, our limited marketingexperience, our dependence on third parties for clinical trials,manufacturing, distribution and quality control and other risks that aredescribed in further detail in the Company's reports filed with the Securitiesand Exchange Commission. We do not plan to update any such forward-lookingstatements and expressly disclaim any duty to update the information containedin this press release except as required by law.COMPANY CONTACTS MEDIA CONTACT Russell Skibsted Susan Neath SVP & Chief Business Officer Porter Novelli Life Sciences 619-849-6007 Paul Arndt Manager, Investor Relations 949-788-6700
SOURCE Spectrum Pharmaceuticals, Inc.